Literature DB >> 25573649

A comparative study of bronchoscopic microsample probe versus bronchoalveolar lavage in patients with burns-related inhalational injury, acute lung injury and chronic stable lung disease.

Suveer Singh1, Vimal Grover, Linsey Christie, Peter Charles, Peter Kelleher, Pallav L Shah.   

Abstract

BACKGROUND AND OBJECTIVES: The bronchoscopic microsample (BMS) probe allows direct epithelial lining fluid (ELF) level measurement without saline lavage. We investigated whether cytokine levels in ELF from a BMS differed from those obtained by bronchoalveolar lavage (BAL) in stable and acute lung disease.
METHODS: In a single-centre, prospective observational cohort study of 45 patients, a sequential BMS probe procedure and BAL were performed on patients with stable chronic obstructive lung disease, interstitial lung disease, acute lung injury (ALI), burns-related inhalational injury or controls. ELF samples were assayed for IL-1β, IL-6, IL-8, TNF-α and G-CSF.
RESULTS: Both bronchoscopic microsampling and BAL showed significantly higher cytokine levels in the ELF from patients with ALI and burns-related inhalational injury than from those with chronic stable lung disease. The BMS method detected cytokine levels approximately 20- to 80-fold higher than the corresponding BAL (uncorrected for dilution). The ratio of BMS and BAL cytokine levels was as follows: the ratio for IL-1β [mean 55, 95% confidence interval (CI) 34-88] was higher than that for IL-6 (mean 16, 95% CI 10-23, p = 0.015) and IL-8 (mean 13, 95% CI -5 to 36, p = 0.03). The ratio for G-CSF (mean 43, 95% CI 24-75) was higher than that for IL-6 (mean 16, 95% CI 10-23, p = 0.008).
CONCLUSIONS: The BMS probe safely collects ELF with higher equivalent inflammatory cytokine concentrations than via BAL from patients with both acute and chronic lung disease and can be an alternative to saline BAL. Variations in cytokine concentrations between BMS and BAL and sampling-site differences warrant further study.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25573649     DOI: 10.1159/000368367

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.

Authors:  Marianne S Muhlebach; Joseph E Hatch; Gisli G Einarsson; Stef J McGrath; Deirdre F Gilipin; Gillian Lavelle; Bojana Mirkovic; Michelle A Murray; Paul McNally; Nathan Gotman; Sonia Davis Thomas; Matthew C Wolfgang; Peter H Gilligan; Noel G McElvaney; J Stuart Elborn; Richard C Boucher; Michael M Tunney
Journal:  Eur Respir J       Date:  2018-07-11       Impact factor: 16.671

2.  Tubeimoside I attenuates inflammation and oxidative damage in a mice model of PM2.5-induced pulmonary injury.

Authors:  Jin-Bo Zhang; Lei Zhang; Shi-Qing Li; Ai-Hua Hou; Wei-Chao Liu; Ling-Ling Dai
Journal:  Exp Ther Med       Date:  2017-12-05       Impact factor: 2.447

Review 3.  Biomarkers in pediatric acute respiratory distress syndrome.

Authors:  Erin F Carlton; Heidi R Flori
Journal:  Ann Transl Med       Date:  2019-10

Review 4.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

5.  Effects of ambient PM2.5 on pathological injury, inflammation, oxidative stress, metabolic enzyme activity, and expression of c-fos and c-jun in lungs of rats.

Authors:  Ruijin Li; Xiaojing Kou; Lizhi Xie; Fangqin Cheng; Hong Geng
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-26       Impact factor: 4.223

Review 6.  Biomarkers for patients with trauma associated acute respiratory distress syndrome.

Authors:  Wujian Xu; Yong Song
Journal:  Mil Med Res       Date:  2017-08-16

7.  The cellular composition of the lung lining fluid gradually changes from bronchus to alveolus.

Authors:  S D Pouwels; Janette K Burgess; Erik Verschuuren; Dirk-Jan Slebos
Journal:  Respir Res       Date:  2021-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.